Cutler Group LP Zynerba Pharmaceuticals, Inc. Call Options Transaction History

Cutler Group LP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Oct 27, 2020	SELL	$3.23 - $4.3 $40,698 - $54,180	-12,600 Reduced 96.18%	500 $0
Q2 2020 Jul 22, 2020	BUY	$3.31 - $6.54 $41,706 - $82,404	12,600 Added 2520.0%	13,100 $2,000
Q1 2020 May 07, 2020	BUY	$2.9 - $6.16 $580 - $1,232	200 Added 66.67%	500 $0
Q4 2019 Feb 06, 2020	SELL	$5.61 - $8.57 $8,415 - $12,855	-1,500 Reduced 83.33%	300 $0
Q2 2019 Aug 09, 2019	SELL	$5.4 - $15.5 $22,140 - $63,550	-4,100 Reduced 69.49%	1,800 $2,000
Q4 2018 Feb 05, 2019	SELL	$2.89 - $7.91 $16,762 - $45,878	-5,800 Reduced 49.57%	5,900 $0
Q3 2018 Nov 07, 2018	BUY	$5.59 - $10.45 $32,981 - $61,654	5,900 Added 101.72%	11,700 $5,000
Q2 2018 Aug 10, 2018	SELL	$7.98 - $12.39 $31,920 - $49,560	-4,000 Reduced 40.82%	5,800 $2,000
Q1 2018 May 11, 2018	SELL	$8.49 - $13.46 $345,543 - $547,822	-40,700 Reduced 80.59%	9,800 $5,000
Q4 2017 Jan 17, 2018	SELL	$8.69 - $14.59 $145,992 - $245,112	-16,800 Reduced 24.96%	50,500 $95,000
Q3 2017 Oct 17, 2017	BUY	$5.73 - $9.44 $385,629 - $635,312	67,300	67,300 $67,000

774K

Ticker ZYNE
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,753,100
Description
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for t...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.